Alert detail
FDA Approval: EBGLYSS (LEBRIKIZUMAB-LBKZ) — Type 1 - New Molecular Entity
Policy ID: FDA-BLA761306Specialty: DermatologyAdded: 6/13/2026Effective: 2024-09-13billing update
Full alert analysis requires a subscription
Subscribe to access the complete alert summary, AI-generated action recommendations, source document links, LCD revision comparisons, and related alerts.